Home Newsfeeds JP Morgan Downgrades Minerva Surgical to Underweight

JP Morgan Downgrades Minerva Surgical to Underweight

JP Morgan analyst Robbie Marcus downgrades Minerva Surgical (NASDAQ:UTRS) from Overweight to Underweight.

byBenzinga Newsdesk

August 10, 2022

1 minute read

JP Morgan analyst Robbie Marcus downgrades Minerva Surgical (NASDAQ:UTRS) from Overweight to Underweight.

Hong Kong Embraces Crypto ETFs: The Gateway To Mainstream Adoption

By Murtuza Merchant

November 11, 10:24 AM

Hong Kong's leaders are currently evaluating the potential to open up the market to exchange-traded funds (ETFs) that would invest directly in cryptocurrencies.

BLK

Digital Ally Files For Common Stock Offering, Size Not Disclosed

By Michael Horton

January 24, 6:26 PM

-SEC Filing

DGLY

Copart, Inc. Announces Senior Leadership Appointments; Hessel Verhage Appointed To Chief Operating Officer, Stephen Powers, Who Has Served As COO, Has Assumed The Role Of Chief Business Development Officer

By Benzinga Newsdesk

January 15, 7:31 PM

Copart, Inc. (NASDAQ:CPRT) is pleased to announce the appointment of three new members to its senior executive leadership team: Chief Marketing Officer (CMO) David (Dave) Kang, Chief Product Officer (CPO) Neel Madhvani,

CPRT

Theriva Biologics Announces Presentation At ESMO Congress 2023 Featuring Survival Outcomes In Phase 1 Study Evaluating VCN-01 In Combination With Durvalumab In Patients With Recurrent/Metastatic Squamous Cell Carcinoma Of The Head And Neck

By Benzinga Newsdesk

October 16, 8:31 AM

-Results from investigator-sponsored study in collaboration with the Institut Catala d'Oncologia (ICO) show enhanced patient survival, correlating with VCN-01 induced upregulation of PD(L)-1- -Key Opinion Leader

TOVX

JP Morgan Downgrades Minerva Surgical to Underweight

Related Posts

Hong Kong Embraces Crypto ETFs: The Gateway To Mainstream Adoption

Digital Ally Files For Common Stock Offering, Size Not Disclosed

Copart, Inc. Announces Senior Leadership Appointments; Hessel Verhage Appointed To Chief Operating Officer, Stephen Powers, Who Has Served As COO, Has Assumed The Role Of Chief Business Development Officer

Theriva Biologics Announces Presentation At ESMO Congress 2023 Featuring Survival Outcomes In Phase 1 Study Evaluating VCN-01 In Combination With Durvalumab In Patients With Recurrent/Metastatic Squamous Cell Carcinoma Of The Head And Neck